Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroid therapy. Outcome and complications.
Identifieur interne : 001053 ( Ncbi/Checkpoint ); précédent : 001052; suivant : 001054Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroid therapy. Outcome and complications.
Auteurs : C J Johns ; S A Schonfeld ; P P Scott ; J B Zachary ; M I MacgregorSource :
- Annals of the New York Academy of Sciences [ 0077-8923 ] ; 1986.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Chloroquine (usage thérapeutique), Facteurs temps, Femelle, Humains, Maladie chronique, Maladies pulmonaires (), Maladies pulmonaires (traitement médicamenteux), Mâle, Population d'origine africaine, Population d'origine européenne, Prednisone (administration et posologie), Prednisone (effets indésirables), Récidive, Sarcoïdose (), Sarcoïdose (traitement médicamenteux), Tests de la fonction respiratoire, Études de suivi.
- MESH :
- administration et posologie : Prednisone.
- effets indésirables : Prednisone.
- traitement médicamenteux : Maladies pulmonaires, Sarcoïdose.
- usage thérapeutique : Chloroquine.
- Adulte, Adulte d'âge moyen, Facteurs temps, Femelle, Humains, Maladie chronique, Maladies pulmonaires, Mâle, Population d'origine africaine, Population d'origine européenne, Récidive, Sarcoïdose, Tests de la fonction respiratoire, Études de suivi.
English descriptors
- KwdEn :
- Adult, African Continental Ancestry Group, Chloroquine (therapeutic use), Chronic Disease, European Continental Ancestry Group, Female, Follow-Up Studies, Humans, Lung Diseases (complications), Lung Diseases (drug therapy), Male, Middle Aged, Prednisone (administration & dosage), Prednisone (adverse effects), Recurrence, Respiratory Function Tests, Sarcoidosis (complications), Sarcoidosis (drug therapy), Time Factors.
- MESH :
- chemical , administration & dosage : Prednisone.
- chemical , adverse effects : Prednisone.
- chemical , therapeutic use : Chloroquine.
- complications : Lung Diseases, Sarcoidosis.
- drug therapy : Lung Diseases, Sarcoidosis.
- Adult, African Continental Ancestry Group, Chronic Disease, European Continental Ancestry Group, Female, Follow-Up Studies, Humans, Male, Middle Aged, Recurrence, Respiratory Function Tests, Time Factors.
Abstract
A series of 181 patients with chronic persistent sarcoidosis for more than 5 years have been reviewed, with a mean follow-up period of 14 years, and 77% followed for more than 10 years. Efforts to identify more white patients meeting the criteria of such persistent disease were unsuccessful. Seventy-eight percent were black, and 69% were women. Pulmonary disease was the major manifestation in 70% and was present in 88%. The early major disease feature predicts the nature of the long-term manifestation in 94%. Ninety-four percent were treated with prednisone, with 63% for more than 5 years. Fifty-three percent required continued treatment, and of those receiving continued treatment, 91% were maintained on doses of no more than 15 mg daily and 65% on no more than 10 mg of prednisone daily. Relapses were frequent as prednisone was withdrawn, occurring at least once in 75% and several times in 51%. Low-dose prednisone treatment with 5-15 mg daily provides significant benefit. A mean treatment period of 8 years was observed (range: 10 days to 24 years). The benefits of treatment greatly exceed the infrequent complications. In Baltimore, chronic sarcoidosis with persistent disease seems to be more frequently encountered in black patients than in white patients.
DOI: 10.1111/j.1749-6632.1986.tb18549.x
PubMed: 3460404
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000588
- to stream PubMed, to step Curation: 000588
- to stream PubMed, to step Checkpoint: 000558
- to stream Ncbi, to step Merge: 001053
- to stream Ncbi, to step Curation: 001053
Links to Exploration step
pubmed:3460404Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroid therapy. Outcome and complications.</title><author><name sortKey="Johns, C J" sort="Johns, C J" uniqKey="Johns C" first="C J" last="Johns">C J Johns</name></author><author><name sortKey="Schonfeld, S A" sort="Schonfeld, S A" uniqKey="Schonfeld S" first="S A" last="Schonfeld">S A Schonfeld</name></author><author><name sortKey="Scott, P P" sort="Scott, P P" uniqKey="Scott P" first="P P" last="Scott">P P Scott</name></author><author><name sortKey="Zachary, J B" sort="Zachary, J B" uniqKey="Zachary J" first="J B" last="Zachary">J B Zachary</name></author><author><name sortKey="Macgregor, M I" sort="Macgregor, M I" uniqKey="Macgregor M" first="M I" last="Macgregor">M I Macgregor</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1986">1986</date><idno type="RBID">pubmed:3460404</idno><idno type="pmid">3460404</idno><idno type="doi">10.1111/j.1749-6632.1986.tb18549.x</idno><idno type="wicri:Area/PubMed/Corpus">000588</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000588</idno><idno type="wicri:Area/PubMed/Curation">000588</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000588</idno><idno type="wicri:Area/PubMed/Checkpoint">000558</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000558</idno><idno type="wicri:Area/Ncbi/Merge">001053</idno><idno type="wicri:Area/Ncbi/Curation">001053</idno><idno type="wicri:Area/Ncbi/Checkpoint">001053</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroid therapy. Outcome and complications.</title><author><name sortKey="Johns, C J" sort="Johns, C J" uniqKey="Johns C" first="C J" last="Johns">C J Johns</name></author><author><name sortKey="Schonfeld, S A" sort="Schonfeld, S A" uniqKey="Schonfeld S" first="S A" last="Schonfeld">S A Schonfeld</name></author><author><name sortKey="Scott, P P" sort="Scott, P P" uniqKey="Scott P" first="P P" last="Scott">P P Scott</name></author><author><name sortKey="Zachary, J B" sort="Zachary, J B" uniqKey="Zachary J" first="J B" last="Zachary">J B Zachary</name></author><author><name sortKey="Macgregor, M I" sort="Macgregor, M I" uniqKey="Macgregor M" first="M I" last="Macgregor">M I Macgregor</name></author></analytic><series><title level="j">Annals of the New York Academy of Sciences</title><idno type="ISSN">0077-8923</idno><imprint><date when="1986" type="published">1986</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>African Continental Ancestry Group</term><term>Chloroquine (therapeutic use)</term><term>Chronic Disease</term><term>European Continental Ancestry Group</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Lung Diseases (complications)</term><term>Lung Diseases (drug therapy)</term><term>Male</term><term>Middle Aged</term><term>Prednisone (administration & dosage)</term><term>Prednisone (adverse effects)</term><term>Recurrence</term><term>Respiratory Function Tests</term><term>Sarcoidosis (complications)</term><term>Sarcoidosis (drug therapy)</term><term>Time Factors</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Chloroquine (usage thérapeutique)</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Maladie chronique</term><term>Maladies pulmonaires ()</term><term>Maladies pulmonaires (traitement médicamenteux)</term><term>Mâle</term><term>Population d'origine africaine</term><term>Population d'origine européenne</term><term>Prednisone (administration et posologie)</term><term>Prednisone (effets indésirables)</term><term>Récidive</term><term>Sarcoïdose ()</term><term>Sarcoïdose (traitement médicamenteux)</term><term>Tests de la fonction respiratoire</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Prednisone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Prednisone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Chloroquine</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Prednisone</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Lung Diseases</term><term>Sarcoidosis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lung Diseases</term><term>Sarcoidosis</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Prednisone</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladies pulmonaires</term><term>Sarcoïdose</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Chloroquine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>African Continental Ancestry Group</term><term>Chronic Disease</term><term>European Continental Ancestry Group</term><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Recurrence</term><term>Respiratory Function Tests</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Facteurs temps</term><term>Femelle</term><term>Humains</term><term>Maladie chronique</term><term>Maladies pulmonaires</term><term>Mâle</term><term>Population d'origine africaine</term><term>Population d'origine européenne</term><term>Récidive</term><term>Sarcoïdose</term><term>Tests de la fonction respiratoire</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A series of 181 patients with chronic persistent sarcoidosis for more than 5 years have been reviewed, with a mean follow-up period of 14 years, and 77% followed for more than 10 years. Efforts to identify more white patients meeting the criteria of such persistent disease were unsuccessful. Seventy-eight percent were black, and 69% were women. Pulmonary disease was the major manifestation in 70% and was present in 88%. The early major disease feature predicts the nature of the long-term manifestation in 94%. Ninety-four percent were treated with prednisone, with 63% for more than 5 years. Fifty-three percent required continued treatment, and of those receiving continued treatment, 91% were maintained on doses of no more than 15 mg daily and 65% on no more than 10 mg of prednisone daily. Relapses were frequent as prednisone was withdrawn, occurring at least once in 75% and several times in 51%. Low-dose prednisone treatment with 5-15 mg daily provides significant benefit. A mean treatment period of 8 years was observed (range: 10 days to 24 years). The benefits of treatment greatly exceed the infrequent complications. In Baltimore, chronic sarcoidosis with persistent disease seems to be more frequently encountered in black patients than in white patients.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Johns, C J" sort="Johns, C J" uniqKey="Johns C" first="C J" last="Johns">C J Johns</name><name sortKey="Macgregor, M I" sort="Macgregor, M I" uniqKey="Macgregor M" first="M I" last="Macgregor">M I Macgregor</name><name sortKey="Schonfeld, S A" sort="Schonfeld, S A" uniqKey="Schonfeld S" first="S A" last="Schonfeld">S A Schonfeld</name><name sortKey="Scott, P P" sort="Scott, P P" uniqKey="Scott P" first="P P" last="Scott">P P Scott</name><name sortKey="Zachary, J B" sort="Zachary, J B" uniqKey="Zachary J" first="J B" last="Zachary">J B Zachary</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001053 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 001053 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:3460404
|texte= Longitudinal study of chronic sarcoidosis with low-dose maintenance corticosteroid therapy. Outcome and complications.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:3460404" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |